Bringing Bones Together™

INVEST IN METRIC MEDICAL DEVICES, INC. TODAY!

Metric Medical Devices, Inc., designs and sells innovative minimally invasive products and technologies for the orthopedic extremity market. Our mission is to become leaders in transforming the musculoskeletal repair standard of care, through the development and commercialization of bone fixation implants that actively change shape to compress the bone to stimulate bone growth and enhance healing.
... Show more
This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Metric Medical Devices, Inc.

REASONS TO INVEST

Reasons Icon

Our founders are highly successful serial entrepreneurs who design implants to promote healing and decrease complications in orthopedic extremity injuries. These implants treat fractures and deformities to improve patients' lives.

Reasons Icon

The orthopedic extremity reconstruction market is projected to reach $6.5 billion, globally, by 2030 at a CAGR of 6.3%. The foot and ankle lower extremity segment, our primary focus, is predicted to experience the largest CAGR of 8.9% from 2021 to 2030 and start with the surgical backlog created by the Covid-19 pandemic.*

Reasons Icon

During development and market trials, our current products generated over $10.5 million in revenue and we have two new next-generation products ready for full launch. We are currently developing our most disruptive product so far, The LINK™, a small bone-compressing external fixator. The market for minimally invasive surgical techniques is growing and is estimated to reach $94.4 billion by 2030 at a CAGR of 4.7%.**


*Information from Allied Market Research, Bloomberg & Becker's Hospital Review (Source | Source | Source)

**Information from Allied Market Research (Source)





OVERVIEW


Improving Treatment in Orthopedics


Metric is focused on creating innovative technology and products to address the serious and persistent issue in musculoskeletal healthcare of deformity correction, fracture repair, and delayed bone healing. We've developed implants that fixate bone fractures and apply forces to the bone to improve healing. Our SuperStaple™ is in-market, our SuperSTEP™ staple and SuperScaffold™ hammer toe implant are FDA cleared for the market, and we are in the process of developing a new product, the LINK™. 


The LINK™ is a minimally invasive external fixation device that is not only compelling in its technology but has the potential to revolutionize how bone fractures are treated. We are designing the LINK™ to allow physicians to treat more patients in their offices because the LINK™ will reduce the need for open surgery. As a result, we believe patients treated with the LINK™ will be able to receive faster care with reduced healthcare costs while adding significant value to the physician's practice.

The Problem & our Solution


Designing Technologies For Better Patient Outcomes

Current treatment methods for osteoarthritis, deformities such as bunions, and small bone fractures, often involve open surgery and have high complication rates ranging from 13-56% (Source). Utilizing NASA’s discovery that a lack of mechanical loading degrades bone, our bone fixation implants change shape to provide compression to improve patient outcomes.



Our upcoming disruptive product, the LINK™, takes this even further. The LINK™ will provide all of the biomechanical and bone-compressing properties proven by our founders and validated through clinical experience, using a revolutionary patent pending external fixation system. We believe our proprietary, minimally-invasive approach will allow for many bony procedures in the foot, ankle, and hand to be performed in-office and without open-surgery. We are prepared to create a business shift from hospital to physician's offices, resulting in earlier treatments, reduced costs, and fewer complications.


*The image animation above on the left is a computer-generated rendering of a future product, the Link™, for functional demonstration purposes. The image above on the right is a pre-production photograph of the Link™. The product is still currently under development and is not yet available on the market.



The Market & our traction


A Fast-Growing Industry and A Successful Track Record

The orthopedic extremity reconstruction market is projected to reach $6.5 billion, globally, by 2030 at a CAGR of 6.3%. The foot and ankle lower extremity segment, our primary focus, is predicted to experience its largest CAGR of 8.9% from 2021 to 2030, owing to baby boomer needs and patients increased awareness about the benefits of lower extremity reconstruction devices. Metric has established initial U.S. distribution of its products and seeks StartEngine investors to help drive value through building a growing and effective sales force.



During product development, we have generated $10.5 million in sales, with a gross profit exceeding 85%. Our technologies are protected by 13 patents in the U.S. with others issued in the UK, Germany, and France, as well as additional patents pending. We have multiple new products ready for full market launch, including the SuperSTEP™ staple and SuperScaffold™ hammer toe implant. Recently, multiple leading physicians have joined us as advisors to develop and advocate for our upcoming product, the LINK™. 

why invest


A New Standard for Orthopedic Treatment


Metric's founders have built a bone-compressing staple company and sold it with a strong return to its investors. Now, we envision Metric Medical Devices to keep building on this experience, launching a broad range of implants to dominate the orthopedic extremity market with minimally-invasive bone compressing products. With next-generation products in hand and disruptive technologies in the pipeline, we believe we are well-equipped and in a position to make that happen. 


We have the innovative, patented technology and proven sales record to bring shareholder value in this fast-growing, multi-billion dollar orthopedic extremity market. Join Metric® as we provide improved minimally invasive care to patients around the world.

Bold (⌘B)

ABOUT

HEADQUARTERS
846 Silver Springs
Helotes, TX 78063
VALUATION
$29.78M

Metric Medical Devices, Inc., designs and sells innovative minimally invasive products and technologies for the orthopedic extremity market. Our mission is to become leaders in transforming the musculoskeletal repair standard of care, through the development and commercialization of bone fixation implants that actively change shape to compress the bone to stimulate bone growth and enhance healing.

TEAM

Dr. William Casey Fox
Dr. William Casey Fox
President, CEO, CTO, and Director

William Casey Fox, Ph.D., P.E.

Dr. Fox conducted pioneering research in bone healing and osteoporosis while at Southwest Research Institute, The University of Texas Health Science Center at San Antonio, and the Texas Biomedical Research Institute and made this a foundational element in two of the companies he founded, BioMedical Enterprises, Inc. (BME) and Agile Manufacturing, Inc. Building products and infrastructure with contract service and Federal, State, and County grant revenue he lead BME in the introduction and establishment of the U.S. market for shape-changing bone-compressing nitinol staples. This success resulted in the sale of BME to Depuy/Synthes, Johnson & Johnson Companies.

A prolific inventor he has had over 35 patents issued in the U.S. and Europe and published tens of articles. Skilled at medical product development, he and his teams have received 20 FDA clearances to market and commercialized the orthopaedic products stemming from his inventions. He has held engineering, advisory board, and adjunct faculty positions over the last 30 years at the institutions listed above as well as the University of Texas at Austin and the University of Alabama, Birmingham. 

Dr. Fox founded and leads Metric Medical Devices, Inc. to broaden and advance the shape-changing bone-compressing orthopaedic implants he pioneered at BME. These next-generation nitinol staples and finger and toe fixation implants enter the market Dr. Fox established. These products are being followed by a disruptive minimally invasive external bone fixator based on these same implant shape-changing concepts. This LINK™ External Fixator will allow bone fixation and compression without open surgery. This is a disruptive concept in bone fixation and may, due to its minimally invasive technique, allow surgeons to treat more bone fractures in their office versus the hospital.

Dr. Fox and his wife Nancy are 37-year residents of San Antonio and native Texans. During his career, he was recognized in 1998 as Ernst & Young’s Entrepreneur of the Year and in 2005 as a Star of Innovation by the San Antonio community. In 2018 he was honored by the University of Texas at Austin’s Cockrell School of Engineering with the highest honor it bestows on its alumni, the Distinguished Alumni Award, and in 2019 he was inducted into the Department of Mechanical Engineering’s Academy of Distinguished Alumni. Dr. Fox is a registered Professional Engineer in the State of Texas and has spent his entire career focused on the orthopaedic problem and entrepreneurism.

Nancy R Fox
Nancy R Fox
CFO & Corporate Secretary

Nancy R. Fox

Chief Financial Officer

Ms. Fox, co-founder, has over 30 years in the medical device industry. She has received awards and a BBA in Accounting at the University of Texas at San Antonio and focuses on operations including managing production, facilities, inventory, shipping/receiving, customer service and human resources. During her almost two decades as CFO of BioMedical Enterprises, Inc. she managed ISO/GMP quality systems, US and International medical product distribution, obtaining the CE mark and managed FDA, ISO and UL systems & audits.

Dr. Gary Frashier

Dr. Gary Frashier

Director, Board of Directors

Gary Frashier is President and Principal of Management Associates, a life sciences consulting group, and brings extensive experience in Life science management, operations and transactions having served as a CEO for twenty-four years in life sciences and specialty chemicals. Prior to the founding of Management Associates, a life science consulting group, Dr. Frashier served as Chief Executive Officer and Chairman of OSI Pharmaceuticals, and it was during his tenure at OSI that the leading genetic-based cancer drug, “Tarceva” was discovered and developed thru human Proof of Concept clinical trials. Tarceva is now sold by Roche and Genentech, with combined total sales of over $15 billion, and with continuing expansion into new cancer areas. OSI was acquired by Astellas Pharma in for $4 billion. He has also been involved in the development and commercialization of two other successful major drugs, one for acute asthma (Zolaire) and the other for relief of Parkinson’s disease. Dr. Frashier has raised over $500 million from a combination of equity financings, and other sources, and has organized many collaborations and joint programs with major pharmaceutical companies.

Prior to OSI, Dr. Frashier served as President, International, and Executive Vice President of Millipore Corporation; President and CEO of Waters Corporation, the leader in liquid chromatography; President of Loctite Corporation’s Americas Group; and CEO of Genex Corporation, a protein engineering company, and Continental Water Systems, Inc. He has participated as a founder of Merrimack Pharmaceuticals, Inc (NASDAQ); Eutropics, Inc; America Stem Cells, Inc; Apex BioVentures Acquisition Corporation; LikeMinds, Inc.; and Xeras, Inc. He currently serves on the boards of several life science companies, including: LikeMinds, Inc., a private radiochemistry imaging company; Xeras, Inc., a private medical device company with products for improving the outcomes of knee replacement surgery; Metric Medical Devices, Inc, a developer and marketer of orthopedic fixation devices. Dr. Frashier has previously served on the Boards of numerous other private and public life science companies, including Maxim Pharmaceuticals, Inex Pharmaceuticals (Canada), Tanox, Inc., Cytoclonal Pharmaceuticals Co.; Exegenics Pharmaceuticals. Inc.; and Aderis, Inc. He is also a Strategic Partner in two of SV Venture funds. He was one of the founders of the New York Biotechnology Association and was selected as the “Long Island Businessman of the Year” by the Wharton Club. Dr. Frashier is an Advisory Trustee of the Southwest Research Institute, and he is chairman of the Chemical Engineering Advisory Board at the University of Texas at San Antonio, and serves on the Board of BioMed SA.

He was recognized by Texas Tech University as a Distinguished Engineer, where he received a B.S. in chemical engineering, and by the Massachusetts Institute of Technology as an Alfred P. Sloan Fellow, where he earned an MBA. He also earned a Ph.D. in innovation leadership from Our Lady of the Lake University. Dr. Frashier is a Registered Professional Engineer in Texas, and he previously served as a First Lieutenant in the U. S. Army Chemical Corps.  

Mr. Jamie Grooms

Mr. Jamie Grooms

Director, Board of Directors

Mr. Grooms co-founded Regeneration Technologies (Nasdaq: RTIX), a publicly-traded company that processes human tissue for allogenic grafts used in orthopedic, oral maxillofacial, urinary, and cardiovascular surgeries. He co-invented the primary value-added technologies that formed the basis of RTIX’s product line. Mr. Grooms also co-founded AxoGen Corporation, and from 2002 to May 2010 he served as Chief Executive Officer. He had been AxoGen Corporation’s Chairman of the Board of Directors since 2002 and then served as AxoGen, Inc.’s Chairman of Board of Directors since 2011. In addition to his executive management experience, he has extensive experience in many areas of med-tech business operations, including R&D, laboratory and manufacturing operations. He has developed state-of-the-art medical processing and manufacturing systems, robotics, and other technological innovations, and has held various leadership positions with LifeNet, Osteotech (Nasdaq:OSTE), and CryoLife (Nasdaq:CRY). Mr. Grooms holds a degree in biology from Old Dominion University.

Dr. Walter Simmons, III

Dr. Walter Simmons, III

Director, Board of Directors

Dr. James Walter Simmons, III, serves as President of the South Texas Spinal Clinic and as one of its Partner and Staff Physicians. He holds Clinical Associate Professor appointments at The University of Texas Health Science Center at San Antonio and Baylor College of Medicine. Dr. Simmons is licensed in Texas, Board Certified by the American Board of Orthopaedic Surgeons and specializes in the treatment of congenital and adult deformity of the spine. In addition to his business leadership as President of his practice group, he founded Trinity Medical, Inc. a topical analgesic technology company and served as Medical Director of and on the Board of Directors of BioMedical Enterprises, Inc. Dr. Simmons was deployed with the 5501st U.S.Army Hospital as a surgeon during the Iraq War and honorably discharged with the rank of Major after eleven years of service. He earned his Bachelor of Science in Biology at the University of Texas at San Antonio, Doctorate in Biochemistry at the University of North Texas, Doctorate of Osteopathy from the Texas College of Osteopathic Medicine, and Masters of Business Administration from the McCombs School of Business, University of Texas at Austin. His Internship and Residence were at The University of Texas Medical Branch in Galveston, Texas and Spine Surgery Fellowship at the Twin Cities Spine Center, Minneapolis, Minnesota. Dr. Simmons has received awards for teaching and research, holds membership in multiple professional societies, and has numerous published works and lectures. Dr. Simmons brings to Metric’s Board of Directors personal experience with the changing healthcare landscape, the physician’s perspective, and strong business acumen.

Stephen Erdner

Stephen Erdner

Vice President Sales

Mr. Erdner has more than 30 years of experience in the orthopedic industry, leading young companies to become respected competitors in their market. He has refined and managed every aspect of sales, marketing and education. His previous work includes BioPro,Inc., where he conceived and developed a national surgical sales distribution network along with a global international presence in six continents. His professional affiliations include past Chairman of the American Academy of Orthopedic Surgeons Advisory Council, where he was awarded the first Honorable Service Award bestowed by the Academy, and is a past member of the American College of Foot and Ankle Surgeons IAC Advisory Council.

Chris Hauser

Chris Hauser

National Sales Manager

Mr. Hauser has over 24 years experience in the medical device arena specializing in Foot & Ankle Orthopedics, Hand and Wrist, Podiatry, Plastics/Reconstruction, and Sports Medicine. Previous work positions include National Sales Manager for Avanta Orthopedics, Regional Sales Manager for Small Bone Innovations, and Regional Sales Manager for BioMedical Enterprises, Inc. with current co-founders.  He also has a Masters in Immunology, which supported his 10+ years of Biological, Immunological, Neurological, and Cardiologic research and multiple publications.

Rhonda Unser

Rhonda Unser

Customer Service Manager

Ms. Unser has over 10 years experience in the medical device industry. She worked previously with co-founders at BioMedical Enterprises, Inc. (BME) as Customer Service Manager. She is currently a co-owner of CoinNews Media Group LLC, San Antonio, TX and is a Director of the Board of First National Bank, Seiling, OK. She holds a BS Psychology from OSU, Stillwater, OK and MS Public Administration, OU, Norman, OK.

Nikki Mabry

Nikki Mabry

Marketing Manager

Ms. Mabry received her BBA in Business Administration and Marketing at the University of Texas at San Antonio. She 5 years of experience in the medical device industry and focuses on building the company’s brand image, studying the market trends, and planning communication strategies to the field.

Scott Williamson

Scott Williamson

Engineering and Production Manager

Mr. Williamson is a graduate of The University of Texas at San Antonio with a B.Sc. in Mechanical Engineering. He has worked in the medical field for over 5 years and currently focuses on the development of medical devices and their systems while managing production logistics.

Dana Mecke

Dana Mecke

Engineer Product Development and Testing

R&D and Product Development Engineer

Dana Mecke has over 10 years of R&D and product development experience in the medical device industry. She holds a M.S. in biomedical engineering from the University of Texas Health Science Center and a B.S. in mechanical engineering from the University of Texas at San Antonio.

Jennie Rogers

Jennie Rogers

Quality and System Administrator

Jennie Rogers has almost 20 years of experience in Production and Quality in the Medical Device realm. Ms. Rogers also lends expertise within IT, Graphic Design, and Photography. She worked previously with co-founders at Biomedical Enterprises, Inc. as both a Production Technician and Quality Assurance Specialist. She holds a BS Criminal Justice from University of Maine at Augusta.

Enrique L. Rosario Aloma, DPM, Ph.D

Enrique L. Rosario Aloma, DPM, Ph.D

Physician Advisor

Dr. Enrique L. Rosario Aloma received his Bachelor of Arts in Chemistry with a concentration in Biochemistry and a minor in both Physics and Biology from Florida International University. He then attended Georgetown University where he received his Doctor of Philosophy in Molecular Biology. He started his teaching career at Nova Southeastern University as an Adjunct Professor of Genetics.           

He completed his Doctor of Podiatric Medicine degree from Barry University and performed his postgraduate work through Barry University’s Mercy Hospital Foot and Ankle Residency Program where he served as resident physician and chief resident.

Dr. Rosario Aloma started working at Barry University School of Podiatric Medicine as Adjunct Professor of Immunology and Microbiology. He is now Assistant Professor at the Barry University School of Podiatric Medicine, Foot and Ankle Institute. He has been published multiple times in Podiatry Institute. His current research, in collaboration with colleague Dr. Luis Rodriguez, is in the field of regenerative medicine and stem cell therapies.

Al D'Angelantonio, DPM, FACFAS

Al D'Angelantonio, DPM, FACFAS

Physician Advisor

Providing surgical and non-surgical management of foot and ankle disorders, Dr. Albert D’Angelantonio, III, DPM, FACFAS sees adults and adolescents (age 12 and up).

Conditions managed include foot and ankle sports injuries, trauma, fractures and sprains, tendonitis, cartilage injuries, skin disorders, heel pain, ganglion cysts, flat feet and arch disorders, arthritis, hammertoes, gait and walking disorders, foot and ankle deformities, and much more.

Dr. D’Angelantonio is an Internationally known expert in Foot and Ankle Surgery. Prior to becoming President and Chief Medical Officer of Integrated Foot and Ankle Specialists, Dr. Albert D’Angelantonio III was at Penn Medicine as Assistant Professor of Surgery in the Division of Plastic and Reconstructive Surgery, where he provided outstanding care from 2012-2022.

Dr. D’Angelantonio was the first faculty member at Penn Medicine with dedicated expertise in foot, ankle and lower leg reconstruction, and became Fellowship Director to share his knowledge and extensive experience with trainees. He got his advanced training as the very first fellow to complete a dedicated lower extremity fellowship within the Division of Plastic Surgery of Penn Medicine at the Hospital of the University of Pennsylvania. His training focused on providing patients with both functional and aesthetic outcomes for all conditions of the foot, ankle, and lower leg. Dr. D’Angelantonio actively educates surgeons from around the world each year. In fact, he is THE foot and ankle surgeon to other surgeons and their families.

He has been recognized:

As one of America's Top Foot and Ankle Surgeons, 2012 - 2021 by the Consumers Research Council of America,

By Best Doctors in America, 2012 - 2021,

By South Jersey Magazine as Top Doctor, 2017 - 2021,

As a Penn Medicine Health Care Hero, 2013 - 2021

Lindsay Barth, DPM

Lindsay Barth, DPM

Physician Advisor

Medical School: University of Osteopathic Medicine and Health Sciences, Des Moines, IA 1995

Residency: Deaconess Incarnate Word Health System, St. Louis, MO 1997

Board Certified: American Board of Podiatric Surgery since 2000

Dr. Barth is President and Founder of Next Step Foot & Ankle Centers. He is a leader in Advanced Foot and Ankle Surgical Techniques.

Dr. Lindsay Barth received his podiatric medical degree at Des Moines College of Podiatric Medicine and Surgery in Des Moines, Iowa. His surgical podiatric residency was completed at Deaconess Hospital in St. Louis, Missouri.

President and founder of Next Step Foot & Ankle Centers, Dr. Barth has been practicing podiatric medicine since 1996. He has been board certified by the American Board of Foot and Ankle Surgery since 2000, and is a leader in Advanced Foot and Ankle surgical techniques. Dr. Barth is a member of the Missouri Podiatric Medical Association, Missouri State Insurance Advisory Board, American Board of Foot and Ankle Surgery, and the American Podiatric Medical Association. Dr. Barth also serves as Chairman of the Political Action Committee.

Dr. Lindsay Barth performed the 1st Wright INBONE total ankle replacement surgery in September of 2007. He is one of the only physicians to offer total ankle replacement services in the St. Louis metro area.

Throughout the Midwest Dr. Barth provides lectures about Podiatric Surgery and Medicine to his peers and students. He is also actively involved in teaching the residents and students at DePaul Hospital. In addition to his position as senior partner of Next Step Foot & Ankle Centers, Dr. Barth has an interest in Walk Healthy Foot Care Products and Medical Spas.

Dr. Barth is an accomplished musician and is a frequent attendee of the St. Louis Symphony. In his spare time, you can find Dr. Barth renovating his 19th century historic home in St. Louis, boating, bicycling, hiking, and gardening.

Dr. Alan Block, DPM, MS, FASPS, FACFAS

Dr. Alan Block, DPM, MS, FASPS, FACFAS

Physician Advisor

EDUCATION:

1978-1980 University of Tennessee, Knoxville, Tennessee

1980-1982 The Ohio State University, Bachelor of Science, Columbus, Ohio

1982-1986 Ohio College of Podiatric Medicine, Doctor of Podiatric Medicine, Cleveland, Ohio

1987-1988 California College of Podiatric Medicine, Master of Science , University of Southern California, Los Angeles, California

CLINICAL TRAINING:

1987-1988 1st Year Podiatric Residency, Circle City Hospital, Corona, California, Robert Parker, DPM

1988-1989 Advanced Ankle Surgery & Sports Medicine, Fellowship, Hayward Foot and Ankle Clinic, Hayward, California, Steven I. Subotnick, DPM, MS

1989-1990 2nd Year Podiatric ResidencyMedical Center Hospital, Portland, Oregon, John Mozena, DPM, Residency Director

BOARD CERTIFIED:

1997 The American Board of Foot and Ankle Surgery, American Council of Certified, Podiatric Physicians and Surgeons

LICENSURE:                                                                               

The State of Ohio

The State of South Carolina

The State of California (Inactive)

EMPLOYMENT:

Palmetto State Surgical Podiatry Associates

Christopher Bromley, DPM

Christopher Bromley, DPM

Physician Advisor

Dr. Christopher Bromley his Doctorate in Podiatric Medicine from the Ohio College Of Podiatric Medicine in Cleveland Ohio. Dr. Bromley graduated with honors and received the Henry Haber Award for Clinical Excellence. He completed his residency program in Podiatric Medicine and Surgery in Baltimore Md, at University of Maryland and Johns Hopkins teaching hospitals. Dr. Bromley is Board Certified in Foot Surgery by the American Board of Podiatric Surgery and is a Fellow of the American College of Foot and Ankle Surgeons. He served as the Chief of Podiatric Medicine at Vassar Brothers Hospital from 2005- 2021 and is a former Director of the St. Francis Hospital Wound Care Center. Dr. Bromley is an international noted expert in Wound Care and Regenerative Medicine and has authored numerous publications. Dr. Bromley currently practices Podiatric Medicine and Surgery in Delray Beach, FL.

Dennis Martin Chaney, DPM

Dennis Martin Chaney, DPM

Physician Advisor

Education: Des Moines University 

DPM, Podiatry

University of Northern Iowa

BS, Biology, Chemistry

Training: Reconstructive Rearfoot and Ankle Fellowship, West Houston Medical Center, Foot and Ankle Surgical Residency, West Houston Medical Center

Dr. Chaney earned his Doctor of Podiatric Medicine (DPM) degree at Des Moines University. He then completed a two-year foot and ankle surgical residency at the West Houston Medical Center in Houston Texas. Dr. Chaney finished his training in Houston by completing a one-year reconstructive Rearfoot and Ankle Fellowship.

Dr. Chaney is board certified in both foot surgery and reconstructive rearfoot and ankle surgery by the American Board of Foot & Ankle Surgery. He has authored numerous papers regarding foot and ankle surgery. He also regularly speaks at regional and national scientific meetings on foot and ankle surgery. Dr. Chaney has served on numerous committees for the American College of Foot & Ankle Surgeons and the American Board of Foot & Ankle Surgery.

Dr. Chaney is involved in residency training as clinical adjunct faculty for the University of Texas Health Science Center at San Antonio.

He specializes in surgical and non-surgical care of all aspects of foot and ankle care including deformity, injuries, sports medicine, diabetes, wound care, dermatology, arthritis and trauma.

Dr. Chaney also specializes 3D Correction for the surgical correction of bunions. This method uses cutting-edge medical instrumentation and fixation to correct your bunion and significantly reducing your likelihood of a recurring bunion. 

Coleman Clougherty, DPM

Coleman Clougherty, DPM

Physician Advisor

Education & Fellowships

Residency - St Vincent Charity Hospital

Cleveland, OH USA 2015

Medical Education - Ohio College of Podiatric Medicine (Kent State College of PM)

Independence, OH USA 2012

Certifications

Foot and Ankle Surgery - Foot Surgery

Foot and Ankle Surgery - Reconstructive Rearfoot and Ankle Surgery

Amram Dahukey, D.P.M., FACFAS

Amram Dahukey, D.P.M., FACFAS

Physician Advisor

Board Certifications and Fellowships and appointments

American Board of Podiatric Surgery, Board Certified in Foot & Ankle Surgery

Fellow, American College of Foot & Ankle Surgeons

Past Director and Founder, TMC and Midwestern University School of Podiatric Medicine Residency Program in Foot and Ankle Surgery. 

Dr. Dahukey is the Co - Past Director and founder of S.A.L.T (Save a Limb Tucson) program at Tucson Medical Center

Director, Sahuaro Research Institute, PLLC

Adjunct Associate Professor Midwestern University College of Health Sciences

Hospital Affiliations:Tucson Medical Center, St. Mary's Hospital, Tucson, Tucson Surgery Center, Northwest Hospital, Tucson

Education

BA, Boston University, Boston MASS BJ Ed Hebrew College Boston Mass DPM, Kent State University College of Podiatric Medicine, Kent OH, Residency, Veterans Affairs Medical Center, Tucson AZ, Professional Memberships Fellow, American College of Foot and Ankle Surgeons Diplomate, American Board of Foot and Ankle Surgery

Personal and professional interests

Dr. Amram Dahukey is the founder and chairman of Premier Foot & Ankle Surgeons. He was born in Jerusalem, Israel. Following completion of his medical education, he attended many post graduate courses and received certification in laser surgery, Ankle Arthroscopy and Endoscopic Surgery. Dr. Dahukey has been awarded Master Surgeon for HyProCure procedure for flat feet, a minimally invasive procedure for correction of flat foot deformity.

Dr. Dahukey is the founder and Past Director of Tucson Medical Center and Midwestern University Podiatric Residency Program, a three year training program in Foot and Ankle Surgery currently trianing nine residents in foot and ankle surgery. He is also the past Director of Save a Limb Tucson (S.A.L.T) program at Tucson Medical Center. Dr. Dahukey is past President of the Arizona Podiatric Medical Association. He is past chairman of the section of Podiatric Surgery at St. Mary’s Hospital, and Tucson Medical Center. Dr. Dahukey is past secretary-treasurer of Arizona State Physician Association. He currently serves on The Pima County Medical Society Board of Directors.

Dr. Dahukeys professional interests include reconstructive foot and ankle surgery, ankle arthroscopy, joint replacement, preventive surgical intervention for diabetic wounds, laser surgery, ingrown toenail, bunion and hammertoe surgery. Dr. Dahukey has been in private practice in Southern Arizona for over 30 years. He is married with two children.

Christopher Edward Gross, MD

Christopher Edward Gross, MD

Physician Advisor

Dr. Christopher E. Gross completed a fellowship at Duke University Medical Center in Foot and Ankle Orthopaedic Surgery after completing his residency training at Rush University Medical Center in Chicago. He graduated from Harvard Medical School.As an orthopaedic foot and ankle surgeon, Dr. Gross is particularly interested in complex reconstruction about the ankle in addition to cartilage injuries that range from small defects to end-stage ankle arthritis. He is also keenly interested in Achilles and other sports-related injuries. He is currently developing a multidisciplinary research division by harnessing the power of biologics and improved implant design, and drug delivery systems. He is the author of over 70 published journal articles, over 30 text book chapters

Philip R. Jenkins, DPM

Philip R. Jenkins, DPM

Physician Advisor

Dr. Philip Ross Jenkins is a Podiatry Specialist in Lenoir, North Carolina. He graduated with honors from Kent State University College Of Podiatric Medicine in 1996. Having more than 26 years of diverse experiences, especially in Podiatry.

CERTIFICATIONS

Foot and Ankle Surgery, Board Certified

Jason Miller, DPM

Jason Miller, DPM

Physician Advisor

Dr. Miller served as Chief Resident and was recognized for assisting in pioneering the foot and ankle program at the 700+ bed Level 1 trauma center in Philadelphia, PA.

Dr. Miller began his career in 2001 teaching in the Department of Surgery at the Temple University School of Podiatric Medicine where he served as Residency Director of the Temple University Health Systems/Northeastern Hospital podiatric residency program and Chief of the section. In 2002, Dr. Miller was honored in the Temple University “Gallery of Success”, an annual prestige that is awarded to a recent and past Temple graduate who has excelled in their chosen career. Dr. Miller continues to hold the rank of Associate Professor as an adjunct faculty member in the Dept. of Surgery at TUSPM. He has been chosen as a Top Doc multiple times in Philadelphia and Main Line Today magazines.

Dr. Miller has written numerous articles in several peer-reviewed journals, presented many poster abstracts at national meetings, written and edited chapters in board review books and lectures both nationally and internationally on a variety of topics related to foot and ankle surgery. He currently serves on the editorial board of the Journal of Foot & Ankle Surgery and The Foot and Ankle Journal Online.

The PA Intensive Lower Extremity Fellowship program was founded by Dr. Miller in 2011 and was recognized by the American College of Foot & Ankle Surgeons as the nation’s first 2 year foot & ankle post-graduate training program. In 2013, he formed a new 3-year residency program at Phoenixville Hospital to serve the community and provide training opportunities for graduating DPM students nationwide.

Naohiro Shibuya, DPM, MS, FACFAS

Naohiro Shibuya, DPM, MS, FACFAS

Physician Advisor

Dr. Shibuya earned his doctoral degree in podiatric medicine at Temple University

School of Podiatric Medicine in Philadelphia and received his Master of Science in

Clinical Investigation from the University of Texas Health Science Center at San

Antonio’s School of Biomedical Sciences. Dr. Shibuya is a Fellow of the American

College of Foot and Ankle Surgery. He was recently appointed Clinical Professor

University of Texas Rio Grande Valley, Edinburg Texas and has been affiliated with

Texas A&M University System Health Science Center, Baylor Scott & White Medical

Center and the Veteran’s Hospital, Temple TX.

Board Certification

Board Certified in Reconstructive and Rearfoot and Ankle Surgery (ABFAS)

Board Certified in Foot Surgery (ABFAS)

Professional Activities

Editor-in-Chief, Journal of Foot and Ankle Surgery 

Scientific Chairman, Annual Meeting of the American College of Foot and Ankle

Surgeons

Member Texas Podiatric Medical Association, Continuing Medical Education

Committee 

Member Faculty, AO North America 

Member Scientific editor, Weekly@eACFAS 

Member Part III National Podiatric Board Examination Item Writing Committee 

Areas of Interest

Foot and Ankle Arthritis Care, Diabetes-Related Foot Conditions, Complete Bunion and

Hammertoe Correction, General and Complex Fracture Repair, Minimally Invasive Foot

and Ankle Surgery

Awards

3rd Place Award, The Effect of Cryotherapy Devices in the Post-Operat  

OPMA 88th Annual Scientific Seminar Resident Paper Finalist competition 

ACFAS 2012, 2011 Annual Scientific Conference, Manuscript Finalist 

2012 - Manuscript, 3rd Place Award, Incidence of Acute Deep Vein Thromb,

ACFAS Annual Scientific Conference 

2005 - 63rd ACFAS Annual Meeting and Scientific Seminar, Manuscript Finalist

James D. Sills-Powell, DPM, MBA, MS

James D. Sills-Powell, DPM, MBA, MS

Physician Advisor

Born and raised in Kansas, Dr. Sills-Powell made a decision to pursue his dream of being a doctor. He attended Barry University's School of Podiatric Medicine and Surgery where he earned his degree in Podiatric Medicine (D.P.M.). He then attended a 3-year surgical residency at SSM DePaul Health Center, located in Bridgeton, Missouri. During his surgical residency, Dr. Sills-Powell received advanced training in forefoot, rear-foot, and ankle surgery, with core rotations through all of the primary departments of the hospital.

Dr. Sills-Powell treats all medical and surgical conditions of the foot and ankle. He has a special interest in wound management, limb salvage and preservation, trauma, and reconstructive foot and ankle surgery.

He is a member in good standing with the APMA (American Podiatric Medical Association) and the APPMA (American Podiatric Practice Management Association). More Than Just Podiatry is also a member of the Western St. Charles County Chamber of Commerce.

Sudheer Reddy, M.D.

Sudheer Reddy, M.D.

Physician Advisor

Sudheer Reddy, M.D., is an orthopaedic surgeon who specializes in the diagnosis and treatment of foot and ankle injuries and conditions, as well as sports related injuries. He joined Shady Grove Orthopaedics in 2017.

After receiving his undergraduate degree, Dr. Reddy earned his medical degree at Albany Medical College, in Albany, New York. He was welcomed as a Junior year member into the Alpha Omega Alpha Medical Honor Society. Dr. Reddy then completed a surgical internship and orthopaedic surgery residency at the Hospital of University of Pennsylvania, in Philadelphia, Pennsylvania.

After finishing his residency, Dr. Reddy completed advanced fellowship training in orthopaedic sports medicine at the University of California-San Francisco, as well as foot and ankle orthopaedic surgery at the Oakland Bone and Joint Center, in Oakland, California.

Dr. Reddy is board-certified by the American Board of Orthopedic Surgery. Additionally, he is a fellow of the American Academy of Orthopaedic Surgeons, and an active member of the American Orthopaedic Foot and Ankle Society.

When Dr. Reddy is not seeing patients, he enjoys traveling, reading about history, and playing tennis.

Thomas Sanders, MD

Thomas Sanders, MD

Physician Advisor

Dr. Thomas Sanders, MD, is an orthopedic foot and ankle specialist certified by the American Board of Orthopaedic Surgery practicing at Orthopaedic Foot & Ankle Center (OFAC) in Falls Church, Virginia. Dr. Sanders specializes in the treatment of ankle arthritis, lower extremity trauma, and fractures of the ankle and foot (calcaneus, talus, and Lisfranc injuries). He also helps patients in the Washington, DC, area with post-traumatic reconstruction, midfoot and forefoot arthritis, flatfoot reconstruction, and bunions/hammertoes. Due to his own sports-related injury, Dr. Sanders has a special interest in minimally invasive and arthroscopic treatments for sports and athletic injuries to the foot and ankle.

Dr. Sanders attended the University of Virginia in Charlottesville for his bachelor's degree and then earned his medical degree and completed his residency at Georgetown University in Washington, DC. During his final year of residency, he served as the administrative chief resident and earned the Hugh. H. Hussey award for excellence in teaching by Georgetown University School of Medicine twice.

After completing his residency, Dr. Sanders went on to complete a fellowship in foot and ankle surgery/lower extremity trauma and reconstruction at the Florida Orthopaedic Institute in Tampa. He received additional, specialized training for both surgical and non-surgical treatments of foot and ankle injuries and diseases, including total ankle arthroplasty. During both his residency and fellowship, Dr. Sanders treated elite level professional, Olympic and collegiate athletes.

Outside of his work at Orthopaedic Foot & Ankle Center, Dr. Sanders is an assistant professor at Georgetown University Medical Center in Washington, DC, and a member of both the American Academy of Orthopaedic Surgeons and American Orthopaedic Foot and Ankle Society.

Daniel Scott, MD, MBA

Daniel Scott, MD, MBA

Physician Advisor

Dr. Daniel Scott is an orthopaedic foot and ankle surgeon at the Medical University of South Carolina. Dr. Scott has extensive experience in total ankle replacements, sports injuries in athletes, post-traumatic reconstruction, fracture care, and complex deformity correction as well as advanced minimally invasive and joint preserving treatment options.As a native of the Carolinas, Dr. Scott graduated with a combined M.D. and MBA degree from Duke University, and went on to complete an orthopaedic surgery residency at Duke University Medical Center. Following this, he completed a fellowship in Foot and Ankle Surgery at Baylor University Medical Center in Dallas, Texas. While at Duke, he was a resident team physician for Duke University athletics, as well as North Carolina Central and Northern High School.Throughout his training, Dr. Scott has received numerous awards for leadership and research. He has been published in a many nationally renowned peer-reviewed journals and has been selected as a reviewer for multiple journals. His work has been presented at numerous local, regional, national, and international meetings.

Jason M Sweeley, DPM

Jason M Sweeley, DPM

Physician Advisor

Jason M Sweeley, DPM is a board certified by the American College of Foot and Ankle Surgeons. He earned his Bachelor of Science degree in Biology from Lycoming College in Williamsport, PA where he graduated Magna Cum Laude. He completed his Doctor of Podiatric Medicine degree at Temple University School of Podiatric Medicine in Philadelphia, PA. Following graduation, Dr. Sweeley completed 3 years of residency training with Pinnacle Health System in Harrisburg, PA where he underwent extensive training in foot and ankle surgery with an emphasis on reconstructive surgery and diabetic limb salvage. He had the distinction of serving as Chief Resident for the 3 years of his residency training.

Dr. Sweeley has advanced training in reconstructive foot and ankle surgery as well as diabetic limb salvage along with training in biomechanical issues and sports medicine. He has completed a micro-vascular surgery course at the Cleveland Clinic and incorporates this training into his surgical approach to neurosurgery including tarsal tunnel decompression. His primary clinical interests include podiatric sports medicine, tarsal tunnel decompression, and rearfoot pathology. His treatment philosophy combines surgical approaches with conservative and non-surgical strategies to restore foot and ankle health and function in both children and adults.

Dr. Sweeley is a Fellow of the American College of Foot and Ankle Surgeons and a member of the American Podiatric Medical Association and the Pennsylvania Podiatric Medical Association.

TERMS

Metric Medical Devices, Inc.
Overview
PRICE PER SHARE
$1.15
DEADLINE
Jan 21, 2023
VALUATION
$29.78M
AMOUNT RAISED
$137,764.05
Breakdown
MIN INVESTMENT
$198.95
MAX INVESTMENT
$1,069,999.10
MIN NUMBER OF SHARES OFFERED
8,695
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
930,434

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Metric Medical Devices, Inc.

Corporate Address

:

846 Silver Springs, Helotes, TX 78063

Offering Minimum

:

$9,999.25

Offering Maximum

:

$1,069,999.10

Minimum Investment Amount

(per investor)

:

$198.95











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

8,695

Maximum Number of Shares Offered

:

930,434

Price per Share

:

$1.15

Pre-Money Valuation

:

$29,780,447.15











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Loyalty Bonus:

Previous investors in Metric Medical will receive an additional 5% bonus shares if they invest in this raise.

All Investors shall receive the Incentive, upon request, of being introduced to Physicians who use Metric Medical Device, Inc. products.

Time-Based:

Community Super Early Birds

Invest within the two weeks and receive 20% bonus shares

Super Early Bird Bonus

Invest within the first three weeks and receive 15% bonus shares

Early Bird Bonus

Invest within the first four weeks and receive 10% bonus shares

Early Bonus

Invest within the first five weeks and received 5% bonus shares

Amount-Based:

$1,000+ Friends

5% bonus shares

$2,000+ Partners

8% bonus shares

$5,000+ Ambassadors

10% bonus shares, access to the Linkedin private discussion group. 

$10,000+ Benefactors

15% bonus shares, access to the Linkedin private discussion group.

$25,000+ Elite Benefactors

20% bonus shares, Video Meeting with Founding Team, and access to the Linkedin private discussion group.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

*Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

The 10% StartEngine Owners' and Incentive Bonus

Metric Medical Devices, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.15 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $115. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

PRESS

Article Image
Covestro

Biocompatible Makrolon® selected for bone fixation device

Article Image
Memry Corporation + Metric Medical Devices, Inc.

SUPER SCAFFOLD™ -A NOVEL NITINOL BONE CONDUCTING SCAFFOLD AND INTERDIGITAL FUSION DEVICE

Article Image
University of Texas at Austin - Cockrell School of Engineering

Dr. Casey Recognized with the 2018 Distinguished Engineering Graduate Award










ALL UPDATES

12.07.22

StartEngine Investors Drive First Week Milestones-Metric Medical Devices

StartEngine Investors Achieved Two Funding Milestones in Metric's First Week with a high average investment of $1,839.

The Metric Team thanks you for your confidence and leadership.

To Metric's 206 Followers: 

Investing the average $1,839 per Follower in Metric will add $378,834 to our raise and you will put us half way to our million dollar raise.

LINK arms with us and invest this week to receive our 15% Time-Based Bonus perk offering.

Dr. Casey Fox










15%
Super Early Bird Bonus

Invest within the first three weeks and receive 15% bonus shares

04
DAYS
15
HOURS
57
MINS
07
SECS
Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Metric Medical Devices, Inc..

$198.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$198.00

Super Early Bird Bonus

Invest within the first three weeks and receive 15% bonus shares

$1,000.00

$1,000+ Friends

5% bonus shares

$2,000.00

$2,000+ Partners

8% bonus shares

$5,000.00

$5,000+ Ambassadors

10% bonus shares, access to the Linkedin private discussion group.

$10,000.00

$10,000+ Benefactors

15% bonus shares, access to the Linkedin private discussion group.

$25,000.00

$25,000+ Elite Benefactors

20% bonus shares, Video Meeting with Founding Team, and access to the Linkedin private discussion group.

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDSWe want you to succeed and get the most out of your money by offering rewards and memberships!
SECUREYour info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTSInvest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.